The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of TH-302, an investigational hypoxia-targeted drug, and dexamethasone in patients with relapsed/refractory multiple myeloma.
Irene M. Ghobrial
No relevant relationships to disclose
Jacob Laubach
No relevant relationships to disclose
Philippe Armand
No relevant relationships to disclose
Erica Boswell
No relevant relationships to disclose
Courtney Hanlon
No relevant relationships to disclose
Stacey Chuma
No relevant relationships to disclose
Esther Dawn Chu
Employment or Leadership Position - Threshold Pharmaceuticals
Stock Ownership - Threshold Pharmaceuticals
Damian Handisides
Employment or Leadership Position - Threshold Pharmaceuticals
Stock Ownership - Threshold Pharmaceuticals
Stew Kroll
Employment or Leadership Position - Threshold Pharmaceuticals
Stock Ownership - Threshold Pharmaceuticals
Barbara Hickingbottom
Employment or Leadership Position - Threshold Pharmaceuticals
Stock Ownership - Threshold Pharmaceuticals
Kenneth Carl Anderson
No relevant relationships to disclose
Paul Gerard Guy Richardson
No relevant relationships to disclose